A single-blind, randomised, phase II UK multi-centre study to determine reactogenicity and immunogenicity of heterologous prime/boost COVID-19 vaccine schedules
Latest Information Update: 08 Nov 2022
At a glance
- Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms Com-COV
- 27 Apr 2021 According to an Oxford Immunotec media release, T-SPOT Discovery SARS-CoV-2 kit will be used for T cell testing in the UK Com-COV trial.The company is collaborating with the Oxford Vaccine Group, part of the team that developed the Oxford-AstraZeneca vaccine, who is leading the Com-COV trial. The trial will help understanding of the effects on the immune response when different combinations of approved COVID-19 vaccines are administered for the first and second immunization doses.
- 09 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 09 Feb 2021 New trial record